Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bazedoxifene + conjugated estrogens is a fixed-dose combination oral medication used in postmenopausal women with an intact uterus to treat moderate to severe vasomotor symptoms (such as hot flashes) and to prevent postmenopausal osteoporosis. Bazedoxifene is a selective estrogen receptor modulator (SERM) that acts as an antagonist in uterine tissue, reducing the risk of endometrial hyperplasia associated with estrogen therapy. Conjugated estrogens are a mixture of naturally occurring estrogen hormones that act as agonists at estrogen receptors, alleviating menopausal symptoms and helping maintain bone density. The combination provides the benefits of hormone replacement while minimizing the need for progestins and reducing certain risks associated with unopposed estrogen therapy[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bazedoxifene + conjugated estrogens.